复星:对于患有慢性阻塞性肺病 (COPD) 的患者来说,是一种潜在的替代治疗剂
Ong Yan Ren1, Yasmeen Siddiqui2, Mohammed Tahir Ansari3
1Centre of Excellence for Postharvest Biotechnology (CEPB), School of Biosciences, University of Nottingham Malaysia, Semenyih, Selangor Darul Ehsan 43500, Malaysia.
Journal of Asian natural products research
|March 10, 2025
概括
Resveratrol通过激活SIRT1并减少氧化应激,显示了慢性阻塞性肺病 (COPD) 的治疗潜力. 封装增强了其在食品和药品中的使用.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 食品科学 食品科学 食品科学
背景情况:
- 慢性阻塞性肺病 (COPD) 是一个主要的全球健康问题.
- 复星是一种天然的多,具有抗氧化和抗炎性质.
- 目前对COPD的治疗选择有局限性,需要新的方法.
研究的目的:
- 审查Resveratrol在COPD治疗中的治疗潜力.
- 探索白醇在肺部保护中的分子和细胞机制.
- 讨论提高生物可用性和应用挑战.
主要方法:
- 对Resveratrol对COPD影响的研究进行文献综述.
- 分析分子通路,包括SIRT1,ROS和Nrf2.
- 检查封装技术,以改善复星的输送.
主要成果:
- 复星激活SIRT1,减少氧化应激和肺组织炎症.
- Nrf2介导的抗氧化酶被白醇上调调节.
- 封装策略改善了用于食品和制药应用的复星的稳定性和生物可用性.
结论:
- Resveratrol对COPD具有显著的治疗前景,可能作为皮质类固醇的替代品.
- 通过封装增强的生物可用性扩大了其在食品强化和制药开发中的用途.
- 需要进一步的研究来克服发展挑战,以便广泛应用.
更多相关视频
相关概念视频
Chronic Obstructive Pulmonary Disease-V: Management
2.5K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.5K
Chronic Obstructive Pulmonary Disease
1.1K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
1.1K
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.7K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.7K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
97
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
97
Chronic Obstructive Pulmonary Disease-I: Introduction
2.7K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
2.7K
COPD: Management Using Bronchodilators and Corticosteroids
117
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
117


